DE69534734D1 - Verwendung von astaxanthin zur verzögerung und verbesserung der augenschädigung - Google Patents

Verwendung von astaxanthin zur verzögerung und verbesserung der augenschädigung

Info

Publication number
DE69534734D1
DE69534734D1 DE69534734T DE69534734T DE69534734D1 DE 69534734 D1 DE69534734 D1 DE 69534734D1 DE 69534734 T DE69534734 T DE 69534734T DE 69534734 T DE69534734 T DE 69534734T DE 69534734 D1 DE69534734 D1 DE 69534734D1
Authority
DE
Germany
Prior art keywords
astaxanthin
delay
eye damage
improve eye
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534734T
Other languages
English (en)
Other versions
DE69534734T2 (de
Inventor
O Tso
Tim-Tak Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
University of Illinois at Urbana Champaign
Original Assignee
University of Illinois
University of Illinois at Urbana Champaign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23288702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69534734(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Illinois, University of Illinois at Urbana Champaign filed Critical University of Illinois
Publication of DE69534734D1 publication Critical patent/DE69534734D1/de
Application granted granted Critical
Publication of DE69534734T2 publication Critical patent/DE69534734T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69534734T 1994-10-27 1995-10-16 Verwendung von astaxanthin zur verzögerung und verbesserung der augenschädigung Expired - Lifetime DE69534734T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/330,194 US5527533A (en) 1994-10-27 1994-10-27 Method of retarding and ameliorating central nervous system and eye damage
US330194 1994-10-27
PCT/US1995/014502 WO1996013255A1 (en) 1994-10-27 1995-10-16 Use of astaxanthin for retarding and ameliorating central nervous system and eye damage

Publications (2)

Publication Number Publication Date
DE69534734D1 true DE69534734D1 (de) 2006-03-30
DE69534734T2 DE69534734T2 (de) 2006-08-17

Family

ID=23288702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534734T Expired - Lifetime DE69534734T2 (de) 1994-10-27 1995-10-16 Verwendung von astaxanthin zur verzögerung und verbesserung der augenschädigung

Country Status (5)

Country Link
US (1) US5527533A (de)
EP (1) EP0786990B1 (de)
CA (1) CA2203836C (de)
DE (1) DE69534734T2 (de)
WO (1) WO1996013255A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747544A (en) * 1995-10-31 1998-05-05 Applied Food Biotechnology, Inc. Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat or prevent retinal degeneration in humans
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US5955102A (en) 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
NL1010351C2 (nl) * 1998-10-19 2001-01-08 Werklust & Beheer B V Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen.
US6730349B2 (en) * 1999-04-19 2004-05-04 Scimed Life Systems, Inc. Mechanical and acoustical suspension coating of medical implants
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US6344214B1 (en) * 1999-12-13 2002-02-05 Cyanotech Corporation Method for retarding and ameliorating fever blisters and canker sores
US7078040B2 (en) * 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US6433025B1 (en) * 2000-04-13 2002-08-13 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
WO2002094253A1 (fr) * 2001-05-24 2002-11-28 Fuji Chemical Industry Co., Ltd. Agents attenuant une erreur de fonction de controle de l'oeil
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
EP1478242B1 (de) * 2002-02-21 2014-04-30 Societe Des Produits Nestle S.A. Futtermittel für haustiere zum schutz der haut gegen licht
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7145025B2 (en) * 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US20060217445A1 (en) * 2003-07-25 2006-09-28 Chew Boon P Natural astaxanthin extract reduces dna oxidation
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
KR101245440B1 (ko) * 2003-09-12 2013-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 사이토킨 조절물질 및 관련된 용도
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
AU2004293105B2 (en) * 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20050130878A1 (en) * 2003-11-26 2005-06-16 Alcon, Inc. Prevention of photic injury by administering a TACE inhibitor
WO2005058064A1 (ja) 2003-12-19 2005-06-30 Menicon Co., Ltd. アスタキサンチン配合ペット用食物
EP1750723A1 (de) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid-analoga oder derivate zur hemmung und linderung von entzündungen
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
DE202006020886U1 (de) 2005-11-28 2010-09-23 U.S. Nutraceuticals Llc Dba Valensa International Algen- und Algenextrakt-Nahrungsergänzungszusammensetzung
US20070293568A1 (en) * 2006-06-16 2007-12-20 Yamaha Hatsudoki Kabushiki Kaisha Neurocyte Protective Agent
CA2692394A1 (en) * 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
JP2011500733A (ja) 2007-10-26 2011-01-06 ケマファー インコーポレーテッド 免疫応答を増強するための組成物および方法
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US9610313B2 (en) 2008-04-10 2017-04-04 U.S. Nutraceuticals Eye health composition and method using plant derived seed extract rich in essential fatty acids derived from perilla seed and carotenoids
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
EP2424512B1 (de) * 2009-04-30 2020-06-03 Avivagen Inc. Verfahren und zusammensetzungen zur verbesserung des gesundheitszustandes von tieren
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US20110021465A1 (en) 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US20110237548A1 (en) 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
EP2417967A1 (de) 2010-07-29 2012-02-15 Visiotact Pharma Transmukosale Zusammensetzung, die Anthocyanine enthält, zum Lindern eines Sehproblems
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
DE212013000066U1 (de) 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
JP6218624B2 (ja) * 2014-01-30 2017-10-25 Ｊｘｔｇエネルギー株式会社 虚血性疾患を予防するための薬剤
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
DE212015000076U1 (de) 2014-03-18 2016-12-06 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin
WO2015142700A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and astaxanthin
WO2015142702A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
WO2015175478A1 (en) 2014-05-13 2015-11-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition using seed oil extracts and phospholipids to enhance absorption of carotenoids and associated methods
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
CN107405507B (zh) 2015-03-02 2022-05-03 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
WO2019083732A1 (en) 2017-10-23 2019-05-02 U.S. Nutraceuticals, Llc D/B/A Valensa International COMPOSITION FOR THE TREATMENT OF PHOTO-INDUCED OCULAR FATIGUE AND THE ASSOCIATED REDUCTION OF OCULAR FOCUSING SPEED IN HUMAN BEINGS
EP3796898A1 (de) 2018-05-24 2021-03-31 U.S. Nutraceuticals, LLC d/b/a Valensa International Zusammensetzung und verfahren zur linderung von gelenkschmerzen mit hyaluronsäure und bestandtellen aus eierschalenmembran
DE202018105422U1 (de) 2018-06-21 2018-10-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920834A (en) * 1970-07-10 1975-11-18 Hoffmann La Roche Light-screening compositions and method
DE69026496D1 (de) * 1989-10-13 1996-05-15 Neurofit Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
FR2664164A1 (fr) * 1990-07-04 1992-01-10 Texinfine Patrinove Composition dermatologique ou cosmetique.
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants

Also Published As

Publication number Publication date
CA2203836C (en) 2004-06-29
EP0786990A1 (de) 1997-08-06
DE69534734T2 (de) 2006-08-17
EP0786990B1 (de) 2006-01-04
CA2203836A1 (en) 1996-05-09
WO1996013255A1 (en) 1996-05-09
US5527533A (en) 1996-06-18

Similar Documents

Publication Publication Date Title
DE69534734D1 (de) Verwendung von astaxanthin zur verzögerung und verbesserung der augenschädigung
ID17437A (id) Metoda dan komposisi untuk membuat kulit terang
DE69622154D1 (de) Verwendung von angiogenese-suppressoren zur hemmung des haarwuchses
DE69712003D1 (de) Modifikation von xylanase zur Verbesserung von Thermophilicität, alkophilicität und thermostabilität
DE69512458D1 (de) Verwendung von Flavonoiden zum Schutz der Haare
ATE331719T1 (de) Verwendung von kristallformen von 2- methylthienobenzodiazepinen
DE69813935D1 (de) Verwendung von Retinoiden zur Induzierung von Hautpigmentierung
DE69517836D1 (de) Proteinhaltiges Mittel zur Verbesserung der Geschmacksqualität von Lebensmitteln
DE69034135D1 (de) DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
DE69732881D1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69327516D1 (de) Verwendung von protein mit erhöhter bakterientötender/durchlassigkeits-erhöhten wirkung und lipid-träger enthaltender zusammensetzung
BR8401746A (pt) Estojo de cosmetico e processo de utilizacao do mesmo
DE69501493D1 (de) Entfernung von Feuchtigkeit und Passivierung von Oberflächen
FI960517A (fi) Kosteita pastatyyppisiä ruoka-aineita ja menetelmä niiden valmistamiseksi
ATE231681T1 (de) Anwendung von dihydroxychinolinverbindungen zur verlängerung der haltbarkeit von säugetier- und fischprodukten
DE69725326D1 (de) Herstellung von fugizides chinazolinonen und nützliche zwischenprodukte
DE69326052D1 (de) Verwendung von dieselschmierstoffe
DE69515070D1 (de) Zusammensetzung auf der Basis von alpha-Pyronen zur Induzierung und Stimulierung des Haarwachstums und/oder zur Verlangsamung des Haarausfalls und ihre Verwendung
DE69636792D1 (de) Verwendung von l-carnitine und acyl derivaten zur senkung des ceramidspiegels
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
DE69510223D1 (de) Herstellung von 2-chlor-2-hydrohexafluorpropan und ihre azeotropen mit hf
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
TR24634A (tr) Guanidin tuerevleri bunlari hazirlamaya mahsus yuentemler ve bunlarin haserelerin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition